[{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"FG-3019","moa":"Connective tissue growth factor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"FG-3019","moa":"Connective tissue growth factor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"FG-3019","moa":"Connective tissue growth factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"FG-3019","moa":"Connective tissue growth factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Oncology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Morgan Stanley Tactical Value","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Financing","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Morgan Stanley Tactical Value","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Morgan Stanley Tactical Value"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Deflazacort","moa":"||Connective tissue growth factor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Deflazacort","moa":"||Connective tissue growth factor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Deflazacort","moa":"||Connective tissue growth factor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Deflazacort","moa":"||Connective tissue growth factor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Deflazacort","moa":"||Connective tissue growth factor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Connective tissue growth factor","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Connective tissue growth factor","graph1":"Oncology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Gemcitabine","moa":"||Connective tissue growth factor","graph1":"Oncology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Genetic Disease","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"FG-3165","moa":"Galectin-9","graph1":"Oncology","graph2":"IND Enabling","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Cemiplimab","moa":"||Galectin-9","graph1":"Oncology","graph2":"IND Enabling","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"FibroGen \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Undisclosed","graph2":"Phase I","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"6","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Undisclosed","graph2":"Phase I","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"6","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Undisclosed","graph2":"Phase I","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"6","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Nephrology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Undisclosed","graph2":"Phase I","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"6","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Undisclosed","graph2":"Phase I","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"6","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Nephrology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Nephrology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Nephrology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Nephrology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Nephrology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"6","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Nephrology","graph2":"Phase I","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"6","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Nephrology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"FibroGen \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ AstraZeneca"},{"orgOrder":0,"company":"FibroGen","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"FibroGen \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ AstraZeneca"},{"orgOrder":0,"company":"FibroGen","sponsor":"Ruijin Hospital | RenJi Hospital | Chang Zheng Hospital | Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Peking University First Hospital | First Affiliated Hospital, Sun Yat-Sen University | First Affiliated Hospital of Zhejiang Unive","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"FibroGen \/ Ruijin Hospital | RenJi Hospital | Chang Zheng Hospital | Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Peking University First Hospital | First Affiliated Hospital, Sun Yat-Sen University | First Affiliated Hospital of Zhejiang Unive","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Ruijin Hospital | RenJi Hospital | Chang Zheng Hospital | Xinhua Hospital, Shanghai Jiaotong University School of Medicine | Peking University First Hospital | First Affiliated Hospital, Sun Yat-Sen University | First Affiliated Hospital of Zhejiang Unive"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Nephrology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"FibroGen \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Astellas Pharma"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Nephrology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"AstraZeneca | Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Nephrology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"FibroGen \/ AstraZeneca | Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ AstraZeneca | Astellas Pharma"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Nephrology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ Astellas Pharma | AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Astellas Pharma | AstraZeneca"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ Astellas Pharma | AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Astellas Pharma | AstraZeneca"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma | AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Nephrology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ Astellas Pharma | AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Astellas Pharma | AstraZeneca"},{"orgOrder":0,"company":"FibroGen","sponsor":"AstraZeneca | Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Oncology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ AstraZeneca | Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ AstraZeneca | Astellas Pharma"},{"orgOrder":0,"company":"FibroGen","sponsor":"AstraZeneca | Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ AstraZeneca | Astellas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ AstraZeneca | Astellas Pharma"},{"orgOrder":0,"company":"FibroGen","sponsor":"NovaQuest Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0.050000000000000003,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ NovaQuest Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ NovaQuest Capital Management"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Astellas Pharma"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Astellas Pharma"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Astellas Pharma"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Nephrology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0.16,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0.16,"dosageForm":"Tablet, Film Coated","sponsorNew":"FibroGen \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ AstraZeneca"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Nephrology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ AstraZeneca"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Nephrology","graph2":"Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"FibroGen \/ AstraZeneca"},{"orgOrder":0,"company":"FibroGen","sponsor":"AstraZeneca | Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Nephrology","graph2":"Phase II","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ AstraZeneca | Astellas Pharma","highestDevelopmentStatusID":"8","companyTruncated":"FibroGen \/ AstraZeneca | Astellas Pharma"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Hematology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ Astellas Pharma","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ Astellas Pharma"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Undisclosed","graph2":"Phase I","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Roxadustat","moa":"Hypoxia-inducible factor prolyl hydroxylase","graph1":"Nephrology","graph2":"Approved FDF","graph3":"FibroGen","amount2":0.22,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0.22,"dosageForm":"Tablet, Film Coated","sponsorNew":"FibroGen \/ AstraZeneca","highestDevelopmentStatusID":"15","companyTruncated":"FibroGen \/ AstraZeneca"},{"orgOrder":0,"company":"FibroGen","sponsor":"Fortis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2023","type":"Licensing Agreement","leadProduct":"FOR46","moa":"Membrane cofactor protein (CD46)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FibroGen","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"7","companyTruncated":"FibroGen \/ FibroGen"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"FOR46","moa":"Membrane cofactor protein (CD46)","graph1":"Oncology","graph2":"Phase I","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"FG-3246","moa":"PSMA","graph1":"Oncology","graph2":"Phase II","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Warfarin Sodium","moa":"Vitamin k epoxide reductase complex subunit 1 isoform 1","graph1":"Undisclosed","graph2":"Phase I","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FibroGen \/ FibroGen","highestDevelopmentStatusID":"6","companyTruncated":"FibroGen \/ FibroGen"}]
Find Clinical Drug Pipeline Developments & Deals by FibroGen
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
